Drugs / KIO-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05629364 | Mar 2023 → Jan 2024 | dry eye syndrome | Kiora Pharmaceuticals, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-03-08 | Kiora Pharmaceuticals, Inc. | Results Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye kiorapharma.com ↗
The study showed that a 12-day treatment of KIO-101 topically at multiple doses was well tolerated in healthy volunteers and patients with inflammation of the eye. |
| 2023-02-07 | Kiora Pharmaceuticals, Inc. | Regulatory Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases kiorapharma.com ↗
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). |
| 2022-04-25 | Kiora Pharmaceuticals, Inc. | Results Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022 kiorapharma.com ↗
The results of the vehicle-controlled, randomized clinical trial in patients with ocular surface inflammation demonstrated safety and tolerability of KIO-101 as well as statistically significant improvements in conjunctival hyperemia in the 0.15% KIO-101 arm compared to vehicle control. |
| 2021-12-14 | Kiora Pharmaceuticals, Inc. | Results Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease kiorapharma.com ↗
The results demonstrated favorable safety and tolerability of KIO-101 as well as statistically significant improvements in conjunctival hyperemia, a key inclusion criterion for the 21 patients enrolled with ocular surface inflammation and a recognized clinical sign in patients with ocular surface inflammation and associated dry eye. |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KIO-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05629364 ↗ |
| Action | Inhibit | “DHODH inhibitor” NCT05629364 ↗ |
| Route | Topical | “.15% KIO-101 eyedrops” NCT05629364 ↗ |
| Target | DHODH | “DHODH inhibitor” NCT05629364 ↗ |